Trial Outcomes & Findings for Driving Simulator Study Comparing Two Modes of Presbyopic Correction With Contact Lenses (NCT NCT02189863)

NCT ID: NCT02189863

Last Updated: 2016-02-18

Results Overview

Driving reaction time to hazards was assessed during simulated night time driving and measured as time to brake, in seconds. One eye (study eye) contributed to the analysis. This outcome measure was prespecified for AOAMV and AOAMF.

Recruitment status

COMPLETED

Study phase

NA

Target enrollment

33 participants

Primary outcome timeframe

Week 2, each period

Results posted on

2016-02-18

Participant Flow

Subjects were recruited from 2 investigational sites located in the UK.

Of the 33 enrolled, 6 participants were exited as screen failures prior to randomization. This reporting group includes all randomized participants who successfully tried at least one study lens (27).

Participant milestones

Participant milestones
Measure
AOAMV, Then AOAMF
Lotrafilcon B MV contact lenses (AOAMV) worn for 2 weeks in Period 1, followed by lotrafilcon B MF contact lenses (AOAMF) worn for 2 weeks in Period 2
AOAMF, Then AOAMV
Lotrafilcon B MF contact lenses worn for 2 weeks in Period 1, followed by lotrafilcon B MV contact lenses worn for 2 weeks in Period 2
First 2 Weeks
STARTED
12
15
First 2 Weeks
COMPLETED
8
13
First 2 Weeks
NOT COMPLETED
4
2
Second 2 Weeks
STARTED
8
13
Second 2 Weeks
COMPLETED
8
13
Second 2 Weeks
NOT COMPLETED
0
0

Reasons for withdrawal

Reasons for withdrawal
Measure
AOAMV, Then AOAMF
Lotrafilcon B MV contact lenses (AOAMV) worn for 2 weeks in Period 1, followed by lotrafilcon B MF contact lenses (AOAMF) worn for 2 weeks in Period 2
AOAMF, Then AOAMV
Lotrafilcon B MF contact lenses worn for 2 weeks in Period 1, followed by lotrafilcon B MV contact lenses worn for 2 weeks in Period 2
First 2 Weeks
Motion Sickness
4
2

Baseline Characteristics

Driving Simulator Study Comparing Two Modes of Presbyopic Correction With Contact Lenses

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Overall
n=27 Participants
Lotrafilcon B MV and lotrafilcon B MF contact lenses worn in Period 1 and Period 2, as randomized
Age, Continuous
55.4 years
STANDARD_DEVIATION 5.4 • n=5 Participants
Sex: Female, Male
Female
17 Participants
n=5 Participants
Sex: Female, Male
Male
10 Participants
n=5 Participants

PRIMARY outcome

Timeframe: Week 2, each period

Population: This analysis population includes all randomized subjects in the groups to which they were randomly assigned who successfully completed both study lens follow-up evaluations without a protocol deviation that was documented as impacting the assessment of the hypotheses (Per-Protocol).

Driving reaction time to hazards was assessed during simulated night time driving and measured as time to brake, in seconds. One eye (study eye) contributed to the analysis. This outcome measure was prespecified for AOAMV and AOAMF.

Outcome measures

Outcome measures
Measure
AOAMV
n=21 Participants
Lotrafilcon B spherical contact lenses worn with 1 eye corrected for distance and 1 eye corrected for near for 2 weeks
AOAMF
n=21 Participants
Lotrafilcon B multifocal contact lenses worn in both eyes for 2 weeks
Driving Reaction Time to Hazards (as Measured by Time to Brake, in Seconds)
1.89 seconds
Standard Deviation 0.22
1.88 seconds
Standard Deviation 0.19

SECONDARY outcome

Timeframe: Week 2, each period

Population: This analysis population includes all randomized subjects in the groups to which they were randomly assigned who successfully completed both study lens follow-up evaluations without a protocol deviation that was documented as impacting the assessment of the hypotheses (Per-Protocol).

The standard deviation of lateral positioning (staying in the lane) was assessed during simulated night time driving and measured as the distance of deviation from the reference point, in meters. This outcome measure is prespecified for AOAMV and AOAMF.

Outcome measures

Outcome measures
Measure
AOAMV
n=21 Participants
Lotrafilcon B spherical contact lenses worn with 1 eye corrected for distance and 1 eye corrected for near for 2 weeks
AOAMF
n=21 Participants
Lotrafilcon B multifocal contact lenses worn in both eyes for 2 weeks
Standard Deviation of Lateral Positioning
0.35 meters
Standard Deviation 0.06
0.35 meters
Standard Deviation 0.05

Adverse Events

AOAMV

Serious events: 0 serious events
Other events: 1 other events
Deaths: 0 deaths

AOAMF

Serious events: 0 serious events
Other events: 1 other events
Deaths: 0 deaths

Lotra B SVD

Serious events: 0 serious events
Other events: 2 other events
Deaths: 0 deaths

Biofinity MF

Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths

Habitual

Serious events: 0 serious events
Other events: 2 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
AOAMV
n=25 participants at risk
Lotrafilcon B spherical contact lenses worn with 1 eye corrected for distance and 1 eye corrected for near for 2 weeks
AOAMF
n=23 participants at risk
Lotrafilcon B multifocal contact lenses worn in both eyes for 2 weeks
Lotra B SVD
n=23 participants at risk
Lotrafilcon B spherical contact lenses worn with both eyes corrected for distance during Period 1 for a same-day assessment
Biofinity MF
n=21 participants at risk
Comfilcon A multifocal contact lenses worn in both eyes during Period 2 for a same-day assessment
Habitual
n=27 participants at risk
Contact lenses worn in both eyes per subject's habitual prescription on Day 1, Period 1, for a same-day assessment
General disorders
Motion sickness
4.0%
1/25 • Adverse events (AEs) were collected for the duration of a subject's participation in the study (up to 4 weeks). This analysis group includes all randomized subjects who successfully tried at least one study lens, based on treatment-specific exposure.
An AE was defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical signs in subjects, users or other persons, whether or not related to the medical device. Ocular adverse events are presented for both study eye and non-study eye.
4.3%
1/23 • Adverse events (AEs) were collected for the duration of a subject's participation in the study (up to 4 weeks). This analysis group includes all randomized subjects who successfully tried at least one study lens, based on treatment-specific exposure.
An AE was defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical signs in subjects, users or other persons, whether or not related to the medical device. Ocular adverse events are presented for both study eye and non-study eye.
8.7%
2/23 • Adverse events (AEs) were collected for the duration of a subject's participation in the study (up to 4 weeks). This analysis group includes all randomized subjects who successfully tried at least one study lens, based on treatment-specific exposure.
An AE was defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical signs in subjects, users or other persons, whether or not related to the medical device. Ocular adverse events are presented for both study eye and non-study eye.
0.00%
0/21 • Adverse events (AEs) were collected for the duration of a subject's participation in the study (up to 4 weeks). This analysis group includes all randomized subjects who successfully tried at least one study lens, based on treatment-specific exposure.
An AE was defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical signs in subjects, users or other persons, whether or not related to the medical device. Ocular adverse events are presented for both study eye and non-study eye.
7.4%
2/27 • Adverse events (AEs) were collected for the duration of a subject's participation in the study (up to 4 weeks). This analysis group includes all randomized subjects who successfully tried at least one study lens, based on treatment-specific exposure.
An AE was defined as any untoward medical occurrence, unintended disease or injury, or untoward clinical signs in subjects, users or other persons, whether or not related to the medical device. Ocular adverse events are presented for both study eye and non-study eye.

Additional Information

Global Brand Lead, Global Medical Affairs, Vision Care

Alcon Research, Ltd.

Phone: 1-888-451-3937

Results disclosure agreements

  • Principal investigator is a sponsor employee Sponsor reserves the right of prior review of any publication or presentation of information related to the study.
  • Publication restrictions are in place

Restriction type: OTHER